drugset
drugset / Trial / NCT06599684

Study of INV-102 Ophthalmic Solution in Adults With Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy

NCT06599684 ↗

Phase 2 Completed 19 enrolled Invirsa, Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Phase 2 study to assess the efficacy of topically administered eyedrops of INV-102 during a 12-week dosing period in subjects with non-center involved DME (NCIDME) associated with NPDR \[Part 1\] and during an 8-week dosing period in subjects with center-involved DME (CIDME) associated with NPDR \[Part 2\].

Timeline

Start
2024-09-07
Primary completion
2025-09-30
Completion
2025-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject INV-102 Unknown 0.7 % Topical

Indications

diabetic macular edema